Aktis Oncology Announces FDA Clearance of…

TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.

A one-year scientific collaboration that included the University of California San Diego and the tiny local biotechnology company TargeGen has moved a treatment for a potentially fatal blood disease into human trials at record speed.

TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.

TargeGen, Inc. today announced that the Company has initiated a multi-center Phase II clinical trial of topically applied TG100801 in patients with age-related macular degeneration (AMD).

TargeGen, Inc. has announced that the Company has successfully closed a $40M venture round of financing.

TargeGen, Inc. has announced that the Company has initiated a single site Phase I clinical trial involving TG100801, a small molecule, topically applied multi-targeted kinase inhibitor for the treatment of macular degeneration and other debilitating diseases of the eye. Macular degeneration is the leading cause of blindness in adults. The trial, involving approximately 45 subjects, is expected to be completed by the end of the first quarter of 2007. The Company hopes to initiate Phase II studies with TG100801 in mid 2007.

TargeGen, Inc., a biopharmaceutical company focusing on the development of small molecule drugs for the treatment of edema and angiogenesis related diseases, today announced that TG 100801, a potent, selective, and topically administered multi target kinase inhibitor, has been designated as a lead drug for clinical development in the treatment of major eye diseases including macular degeneration, diabetic macular edema and diabetic retinopathy. Current treatments for wet macular degeneration have demonstrated limited efficacy to date and require injection into the eye, thus increasing the risk of infection and retinal detachment.